Simplify Logo

Full-Time

Regulatory Associate I/II

Posted on 7/23/2024

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops allogeneic gamma delta T cell therapies

Hardware
Biotechnology
Healthcare

Compensation Overview

$105k - $146kAnnually

+ Annual Cash Bonus + Long-term Incentives + Employee Stock Purchase Plan

Junior, Mid

San Carlos, CA, USA

Category
Risk & Compliance
Legal & Compliance
Required Skills
Communications
Word/Pages/Docs
Requirements
  • Bachelor's degree in life sciences or a relevant field, advanced degree preferred
  • 2-5 years working within the biotech/pharmaceutical industry, 1+ years of experience in regulatory affairs preferred
  • Prior experience with cell or gene therapies is highly preferred
  • Strong organizational skills and attention to detail
  • Ability to prioritize projects based on input from Manager
  • Strong verbal and written communication skills and interpersonal skills
  • Proficiency in Microsoft Word and Excel
  • Experience with Microsoft Power Point, MS Project, and Smartsheet preferred
Responsibilities
  • Support, prepare and/or coordinate routine regulatory submissions and other correspondence
  • Assist with creating and maintaining regulatory timelines and tracking deliverables
  • Interface with functional areas to obtain information required for regulatory submissions
  • Assist the team in executing regulatory strategy options
  • Monitor regulatory environment for changes to requirements
  • Maintain current knowledge and expertise of FDA/EMA regulations and ICH guidelines
  • Collaborate in preparing and maintaining SOPs and appropriate regulatory operating guidelines
  • Perform workflows and procedures regarding document tracking, indexing, and disseminating information
  • Serve as Regulatory support team member assisting cross-functional project teams

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is positioned to improve cancer treatment outcomes through its unique immunotherapy approach.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

39%
Simplify Jobs

Simplify's Take

What believers are saying

  • Adicet Bio's strong financial position, with $247.6 million in cash and cash equivalents, provides a solid foundation for continued R&D and clinical trials.
  • The promising preclinical data on ADI-270 and the initiation of multiple Phase 1 trials highlight the company's robust pipeline and potential for breakthrough therapies.
  • The company's strategic focus on both solid and hematological cancers, as well as autoimmune diseases, increases the likelihood of successful treatments and market adoption.

What critics are saying

  • The clinical and regulatory landscape for new cancer therapies is highly competitive and uncertain, posing risks to Adicet Bio's market entry and adoption.
  • The reliance on successful clinical trial outcomes for ADI-001 and ADI-270 introduces significant uncertainty and potential delays in commercialization.

What makes Adicet Bio, Inc unique

  • Adicet Bio's use of allogeneic gamma delta T cells offers an 'off-the-shelf' solution, providing faster and potentially more effective cancer treatments compared to autologous therapies.
  • The company's focus on both cancer and autoimmune diseases broadens its market reach and potential impact, unlike competitors who may focus solely on one area.
  • Adicet Bio's recent merger with resTORbio and significant funding rounds, including an $80 million Series B, bolster its R&D capabilities and accelerate its path to commercialization.
INACTIVE